Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore's gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder ("PTSD")

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8-$32.0 Million
TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore Announces Third Quarter 2025 Financial Results
electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
electroCore Announces Reimbursement Approval for gammaCore(TM) by RIZIV/INAMI in Belgium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.